Advanced search
Publication Cover
Acta Oncologica Volume 51, 2012 - Issue 1
Journal homepage
912
Views
9
CrossRef citations to date
0
Altmetric
Research Article

Safety and efficacy of temsirolimus in heavily pretreated patients with metastatic renal cell carcinoma

Wolfgang LammClinical Division of Oncology and Cancer Centre, Department of Medicine I, Medical University of Vienna, Austria Waehringerguertel 18-20, A-1090 Vienna, AustriaCorrespondence[email protected]
,
Ursula Maria VoglClinical Division of Oncology and Cancer Centre, Department of Medicine I, Medical University of Vienna, Austria Waehringerguertel 18-20, A-1090 Vienna, Austria
,
Marija BojicClinical Division of Oncology and Cancer Centre, Department of Medicine I, Medical University of Vienna, Austria Waehringerguertel 18-20, A-1090 Vienna, Austria
,
Christoph ZielinskiClinical Division of Oncology and Cancer Centre, Department of Medicine I, Medical University of Vienna, Austria Waehringerguertel 18-20, A-1090 Vienna, Austria
,
Christoph KlinglerDepartment of Urology, Medical University of Vienna, Austria Waehringerguertel 18-20, A-1090 Vienna, Austria
,
Gero KramerDepartment of Urology, Medical University of Vienna, Austria Waehringerguertel 18-20, A-1090 Vienna, Austria
&
Manuela SchmidingerClinical Division of Oncology and Cancer Centre, Department of Medicine I, Medical University of Vienna, Austria Waehringerguertel 18-20, A-1090 Vienna, Austria
 show all
Pages 101-106 | Received 31 Jan 2011, Accepted 14 May 2011, Published online: 08 Jul 2011

Citations (9)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

F Stenner-Liewen, V Grünwald, R Greil & C Porta. (2013) The clinical potential of temsirolimus in second or later lines of treatment for metastatic renal cell carcinoma. Expert Review of Anticancer Therapy 13:9, pages 1021-1033.
Read now
Alessandra Felici, Emilio Bria, Giampaolo Tortora, Francesco Cognetti & Michele Milella. (2012) Sequential therapy in metastatic clear cell renal carcinoma: TKI–TKI vs TKI–mTOR. Expert Review of Anticancer Therapy 12:12, pages 1545-1557.
Read now

Articles from other publishers (7)

Jonathan W. Goldman, Melody A. Mendenhall & Sarah R. Rettinger. (2016) Hyperglycemia Associated With Targeted Oncologic Treatment: Mechanisms and Management. The Oncologist 21:11, pages 1326-1336.
Crossref
Hideaki Miyake, Ken-ichi Harada, Masafumi Kumano & Masato Fujisawa. (2013) Assessment of efficacy, safety and quality of life of 55 patients with metastatic renal cell carcinoma treated with temsirolimus: a single-center experience in Japan. International Journal of Clinical Oncology 19:4, pages 679-685.
Crossref
Masafumi Kumano, Hideaki Miyake, Ken-ichi Harada & Masato Fujisawa. (2013) Sequential use of mammalian target of rapamycin inhibitors in patients with metastatic renal cell carcinoma following failure of tyrosine kinase inhibitors. Medical Oncology 30:4.
Crossref
Hideaki Miyake, Ken-ichi Harada, Yuji Kusuda & Masato Fujisawa. (2012) Efficacy and safety of temsirolimus in Japanese patients with metastatic renal cell carcinoma on hemodialysis. International Journal of Clinical Oncology 18:6, pages 1054-1059.
Crossref
JOSÉ MIGUEL JURADO, IRENE ZARCOS, MAYTE DELGADO, ISABEL BLANCAS, MARTA LEGERÉN & JOSÉ LUIS GARCÍA-PUCHE. (2013) Temsirolimus in overtreated metastatic renal cancer with subsequent use of sunitinib: A case report. Oncology Letters 5:4, pages 1382-1384.
Crossref
Stefan Hart, Veronica Novotny-Diermayr, Kee Chuan Goh, Meredith Williams, Yong Cheng Tan, Lai Chun Ong, Albert Cheong, Bee Kheng Ng, Chithra Amalini, Babita Madan, Harish Nagaraj, Ramesh Jayaraman, Khalid M. Pasha, Kantharaj Ethirajulu, Wee Joo Chng, Nurulhuda Mustafa, Boon Cher Goh, Cyril Benes, Ultan McDermott, Mathew Garnett, Brian Dymock & Jeanette M. Wood. (2013) VS-5584, a Novel and Highly Selective PI3K/mTOR Kinase Inhibitor for the Treatment of Cancer. Molecular Cancer Therapeutics 12:2, pages 151-161.
Crossref
S. Aissi, M. Ben Mrad, S. Zarraa, A. Bounedjar, S. Laabidi & H. Boussen. (2012) Thérapies anticancéreuses ciblées : vers une nouvelle toxicologie ?. Pathologie Biologie 60:4, pages 234-238.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.